NO3124025T3 - - Google Patents

Info

Publication number
NO3124025T3
NO3124025T3 NO16181821A NO16181821A NO3124025T3 NO 3124025 T3 NO3124025 T3 NO 3124025T3 NO 16181821 A NO16181821 A NO 16181821A NO 16181821 A NO16181821 A NO 16181821A NO 3124025 T3 NO3124025 T3 NO 3124025T3
Authority
NO
Norway
Application number
NO16181821A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3124025(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3124025T3 publication Critical patent/NO3124025T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO16181821A 2015-07-31 2016-07-29 NO3124025T3 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1557412A FR3039401B1 (fr) 2015-07-31 2015-07-31 Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Publications (1)

Publication Number Publication Date
NO3124025T3 true NO3124025T3 (zh) 2018-07-28

Family

ID=55299545

Family Applications (1)

Application Number Title Priority Date Filing Date
NO16181821A NO3124025T3 (zh) 2015-07-31 2016-07-29

Country Status (40)

Country Link
US (1) US20170027952A1 (zh)
EP (1) EP3124025B1 (zh)
JP (2) JP2017061445A (zh)
KR (1) KR101822492B1 (zh)
CN (1) CN106397427A (zh)
AR (1) AR105527A1 (zh)
AU (1) AU2016206300A1 (zh)
BR (1) BR102016017404A2 (zh)
CA (1) CA2936904C (zh)
CL (1) CL2018000256A1 (zh)
CO (1) CO2018000953A2 (zh)
CR (1) CR20180044A (zh)
CU (1) CU20180013A7 (zh)
CY (1) CY1120792T1 (zh)
DK (1) DK3124025T3 (zh)
EA (1) EA032217B1 (zh)
EC (1) ECSP18003671A (zh)
ES (1) ES2671133T3 (zh)
FR (1) FR3039401B1 (zh)
HR (1) HRP20180760T1 (zh)
HU (1) HUE037632T2 (zh)
IL (1) IL257232A (zh)
LT (1) LT3124025T (zh)
MA (1) MA39693B1 (zh)
MD (1) MD3124025T2 (zh)
ME (1) ME03052B (zh)
MX (1) MX366748B (zh)
NO (1) NO3124025T3 (zh)
PE (1) PE20190350A1 (zh)
PH (1) PH12016000248A1 (zh)
PL (1) PL3124025T3 (zh)
PT (1) PT3124025T (zh)
RS (1) RS57057B1 (zh)
RU (1) RU2695362C2 (zh)
SG (1) SG10201605664SA (zh)
SI (1) SI3124025T1 (zh)
SV (1) SV2018005615A (zh)
TN (1) TN2018000028A1 (zh)
TW (1) TWI623315B (zh)
WO (1) WO2017021634A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101956978B1 (ko) * 2015-05-18 2019-03-12 주식회사 케이티 시스템 정보 송수신 방법 및 그 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2492864C2 (ru) * 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения рака, несущего мутации egfr
EP2131845B1 (en) * 2007-03-01 2012-04-11 Novartis AG 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide mesylate, hydrates and polymorphs thereof, and formulations comprising these forms
CA2680161A1 (en) * 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5945863B2 (ja) * 2012-01-06 2016-07-05 国立大学法人高知大学 腎細胞がん治療剤
EP2964260A2 (en) * 2013-03-06 2016-01-13 F. Hoffmann-La Roche AG Methods of treating and preventing cancer drug resistance
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US20160324855A1 (en) * 2014-01-07 2016-11-10 Merck Patente Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with gefitinib
US20170304313A1 (en) * 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer

Also Published As

Publication number Publication date
SG10201605664SA (en) 2017-02-27
MD3124025T2 (ro) 2018-06-30
TWI623315B (zh) 2018-05-11
US20170027952A1 (en) 2017-02-02
RU2016131395A3 (zh) 2018-06-08
ME03052B (me) 2018-10-20
BR102016017404A2 (pt) 2017-02-07
KR101822492B1 (ko) 2018-01-29
EA201600507A3 (ru) 2017-03-31
RU2695362C2 (ru) 2019-07-23
CR20180044A (es) 2018-04-03
CU20180013A7 (es) 2018-05-08
CA2936904C (fr) 2018-12-04
MA39693B1 (fr) 2018-07-31
KR20170015218A (ko) 2017-02-08
WO2017021634A1 (fr) 2017-02-09
ES2671133T3 (es) 2018-06-05
MX2016009743A (es) 2017-03-03
JP2017061445A (ja) 2017-03-30
EA032217B1 (ru) 2019-04-30
ECSP18003671A (es) 2018-03-31
IL257232A (en) 2018-03-29
AR105527A1 (es) 2017-10-11
EP3124025B1 (fr) 2018-02-28
FR3039401A1 (fr) 2017-02-03
CL2018000256A1 (es) 2018-04-06
FR3039401B1 (fr) 2018-07-13
CA2936904A1 (fr) 2017-01-31
RU2016131395A (ru) 2018-02-02
JP2019163306A (ja) 2019-09-26
HRP20180760T1 (hr) 2018-06-15
CN106397427A (zh) 2017-02-15
PL3124025T3 (pl) 2018-06-29
PT3124025T (pt) 2018-04-09
MX366748B (es) 2019-07-23
CO2018000953A2 (es) 2018-07-10
SI3124025T1 (en) 2018-04-30
EA201600507A2 (ru) 2017-02-28
TN2018000028A1 (fr) 2019-07-08
HUE037632T2 (hu) 2018-09-28
LT3124025T (lt) 2018-03-26
AU2016206300A1 (en) 2017-02-16
EP3124025A1 (fr) 2017-02-01
PE20190350A1 (es) 2019-03-07
MA39693A (fr) 2017-02-01
DK3124025T3 (en) 2018-06-06
SV2018005615A (es) 2018-05-14
TW201711686A (zh) 2017-04-01
CY1120792T1 (el) 2019-12-11
RS57057B1 (sr) 2018-05-31
PH12016000248A1 (en) 2018-01-22

Similar Documents

Publication Publication Date Title
BR112018002822A2 (zh)
BR112018004764A2 (zh)
BR112017027395A2 (zh)
BR112017026493A2 (zh)
BR112018004375A2 (zh)
RU2016131395A3 (zh)
BE2015C047I2 (zh)
BE2015C044I2 (zh)
BR0009942B1 (zh)
BR0002402B1 (zh)
BR0009182B1 (zh)
BR0009349B1 (zh)
BR0007834B1 (zh)
BR0009373B1 (zh)
BR0007747B1 (zh)
BR0000126B1 (zh)
BR0009649B1 (zh)
BR0009717B1 (zh)
BR0009757B1 (zh)
BR0000695B1 (zh)
BR0000763F1 (zh)
BR0001536B1 (zh)
BR0001684B1 (zh)
BR0009761B1 (zh)
BR0008158B1 (zh)